• SB203580: Mechanism-First p38 Assay Design

  2026-08-23

  Discover how SB203580 can be used to dissect p38 MAPK signaling in regenerative biomaterials research. This guide translates a magnetic exosome hydrogel study into practical assay controls, interpretation strategies, and formulation-aware experimental decisions.

• Pemetrexed Workflows for Tumor Biology Research

  2026-08-22

  Build reproducible antifolate assays with Pemetrexed across tumor cell lines, including non-small cell lung carcinoma and mesothelioma models. This guide combines dose-response design, formulation controls, DNA-repair-focused combinations, and troubleshooting strategies for more interpretable cancer chemotherapy research.

• Fasudil (HA-1077) HCl ROCK Workflows

  2026-08-21

  Build reproducible ROCK inhibition experiments with Fasudil (HA-1077) HCl across proliferation, migration, and apoptosis assays. This guide combines practical dosing, pathway-focused readouts, storage guidance, and a cautious extension of recent Hippo signaling research.

• 2-NBDG Maps Metabolic Context in Sorafenib Resistance

  2026-08-20

  A translational framework for using fluorescent glucose uptake measurements to extend mechanistic studies of HNF4A-AS1, lipid metabolism, ferroptosis, and sorafenib resistance in hepatocellular carcinoma.

• Thiazovivin (A5506): Practical ROCK Inhibitor Guide

  2026-08-20

  Thiazovivin is a ROCK inhibitor used to address poor cell recovery after dissociation and low efficiency during fibroblast reprogramming for induced pluripotent stem cell generation. This guide covers stock handling, controls, workflow integration, and limitations; it is for scientific research only and not for diagnostic, clinical, or medical use.

• BGJ398 Workflows for FGFR Signaling Research

  2026-08-19

  BGJ398 (NVP-BGJ398) combines nanomolar FGFR1/2/3 activity with a focused selectivity profile for dissecting receptor-dependent biology. This guide translates that pharmacology into oncology, cell-based, and developmental-tissue workflows while emphasizing formulation control, orthogonal readouts, and model-specific interpretation.

• Indomethacin as a Mechanistic Probe in Inflammation

  2026-08-19

  Indomethacin is more than a cyclooxygenase inhibitor: it is a versatile probe for inflammation research, PPAR biology, lipid metabolism, and membrane signaling. This article translates a recent FXR–KLF11 kidney-injury study into a rigorous framework for designing and interpreting indomethacin experiments.

• WZ4003: A NUAK1/2 Inhibitor for Cell Assays

  2026-08-18

  WZ4003 enables target-focused studies of NUAK1/2 signaling across migration, proliferation, invasion, and tau phosphorylation workflows. This practical guide connects biochemical selectivity with cell-based controls and the contrasting responses observed in mouse versus human brain slice cultures.

• Erythrocyte-Mimicking Nanovesicles for Periodontitis

  2026-08-18

  Tang and colleagues developed gallium-porphyrin-loaded erythrocyte membrane nanovesicles that exploit the heme-acquisition biology of Porphyromonas gingivalis. The formulation combines bacterial targeting, metabolic disruption, and blue-light photodynamic activity to inhibit P. gingivalis, reduce epithelial invasion, and alleviate periodontitis progression.

• Cholecystokinin Octapeptide Ammonium Workflow

  2026-08-17

  Build reproducible neurobehavioral, neuronal survival, immune, and cardiac signaling assays with a sulfated CCK-8 workflow designed around receptor context and dose. This guide combines historical CNS pharmacology with practical handling, fresh-solution discipline, controls, and troubleshooting for CCK-8 ammonium experiments.

• Scalable EPSC-iMSC EV Manufacturing: Study Insights

  2026-08-17

  Gong et al. describe a bioreactor-based platform that generates induced mesenchymal stem cells from extended pluripotent stem cells and produces extracellular vesicles at a scale relevant to translational research. The study combines suspension expansion, fixed-bed processing, standardized EV characterization, and pulmonary fibrosis testing to address donor variability and limited manufacturing capacity.

• Thiazovivin (A5506): ROCK Inhibitor Workflow Guide

  2026-08-16

  Thiazovivin (A5506) is a ROCK inhibitor intended to support fibroblast reprogramming and recovery of human embryonic stem cells after trypsinization. This guide focuses on stock handling, controls, and workflow validation; the compound is for scientific research only and should not be used for diagnostic, clinical, or medical applications.

• Palonosetron hydrochloride in Cell Assays

  2026-08-15

  Learn how Palonosetron hydrochloride, SKU B2229, can improve mechanistic control in receptor, transporter, viability, proliferation, and cytotoxicity workflows. This scenario-based guide connects concentration selection, solvent compatibility, data interpretation, and supplier reliability to published potency and product data.

• Tenofovir vs Entecavir After HBV-Related HCC Resection

  2026-08-14

  This retrospective cohort study compared tenofovir disoproxil with Entecavir after curative liver resection for HBV-related hepatocellular carcinoma. Propensity-matched results associated tenofovir disoproxil with better long-term overall and recurrence-free survival, while also illustrating the limits of applying postoperative comparative evidence to broader chronic hepatitis B infection therapy.

• TAI-1: Hec1 Inhibitor Workflow Guide

  2026-08-14

  TAI-1 provides a mechanistically distinct way to study mitotic vulnerability through Hec1–Nek2 disruption, chromosomal misalignment, and apoptotic cell death induction. This workflow connects dose-response, imaging, apoptosis, combination, and transcription–replication conflict assays for more informative cancer cell proliferation inhibition studies.

8686 records 1/580 page Next 12345 下5页 Last page